<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103545</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 2.8</org_study_id>
    <nct_id>NCT00103545</nct_id>
  </id_info>
  <brief_title>Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response</brief_title>
  <official_title>A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Study Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to use an immunologic approach following the treatment for
      recurrent disease in patients with ovarian, fallopian tube, or peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with epithelial ovarian, fallopian tube or peritoneal cancer who receive surgical
      cytoreduction and platinum/taxane containing chemotherapy have a significant chance of
      entering complete clinical remission but about 70% will eventually relapse. Many patients
      respond to additional cytotoxic treatment with partial or complete responses, yet
      approximately 100% of these patients will ultimately progress. Novel consolidation strategies
      following treatment for recurrent disease are needed and an immunologic approach is an
      attractive option.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date>August 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, feasibility and tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary endpoint is drop-out due to toxicity as the overall measure of feasibility</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration and strength of the immune response induced by ACA 125 vaccination</measure>
  </secondary_outcome>
  <enrollment>36</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Peritoneal Neoplasms</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACA 125</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with epithelial carcinoma arising in the ovary, fallopian tube or peritoneum,
             stages I-IV. These patients must have received initial surgery and chemotherapy with
             at least one platinum based chemotherapy regimen.

          -  Patients must have relapsed and now have completed chemotherapy for recurrent disease
             within the last 6 weeks.

          -  Eligible patients may have asymptomatic residual measurable disease on CT scan, and/or
             may have an elevated CA-125, or may be in complete clinical remission.

          -  Patients must have adequate hematologic, renal and hepatic functions.

        Exclusion Criteria:

          -  Patients with any other active malignancy concomitantly

          -  Patients within 3 weeks of prior cytotoxic or investigational chemotherapy

          -  Patients within 4 weeks of prior radiotherapy

          -  Patients within 6 weeks of prior immunotherapy

          -  Patients who have received any prior anti-cancer vaccine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacobus Pfisterer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGO Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for Gynecology and Gyn. Oncology, Humboldt University</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Carl Gustav Carus, Gynecological hospital</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecologic Hospital</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Clinic of the Ernst-Moritz-Arndt-University</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Schleswig-Holstein, Campus Kiel, Clinic for gynecology and obstetrics</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke University, University Gynecological Hospital</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of the Philipps University Marburg, Clinic for gynecology, gyn. endocrinology and oncology</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gynecological Hospital</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Gnyecology and gyn. Oncology HSK</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ago-ovar.de</url>
    <description>Information on studies of the AGO-OVAR on Ovarian cancer</description>
  </link>
  <reference>
    <citation>Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006 Oct;17(10):1568-77.</citation>
    <PMID>17005631</PMID>
  </reference>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2005</study_first_submitted>
  <study_first_submitted_qc>February 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2005</study_first_posted>
  <last_update_submitted>September 29, 2006</last_update_submitted>
  <last_update_submitted_qc>September 29, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2006</last_update_posted>
  <keyword>Ovarian Cancer</keyword>
  <keyword>ACA 125</keyword>
  <keyword>6 or 9 vaccinations</keyword>
  <keyword>immune response</keyword>
  <keyword>Fallopian tube cancer</keyword>
  <keyword>Peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

